Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-4ddd1ab0c737d818a0282b987d49df2b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-4ddd1ab0c737d818a0282b987d49df2b"/>
<resource>
<Composition>
<id value="composition-en-4ddd1ab0c737d818a0282b987d49df2b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-4ddd1ab0c737d818a0282b987d49df2b"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-4ddd1ab0c737d818a0282b987d49df2b</b></p><a name="composition-en-4ddd1ab0c737d818a0282b987d49df2b"> </a><a name="hccomposition-en-4ddd1ab0c737d818a0282b987d49df2b"> </a><a name="composition-en-4ddd1ab0c737d818a0282b987d49df2b-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/96/018/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - rapilysin</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/96/018/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp4ddd1ab0c737d818a0282b987d49df2b"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - rapilysin"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Rapilysin is and what it is used for</li><li>What you need to know before Rapilysin is given to you</li><li>How to use Rapilysin</li><li>Possible side effects</li><li>How to store Rapilysin</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What rapilysin is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What rapilysin is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Rapilysin contains the active substance reteplase(a recombinant plasminogen activator). It is a thrombolytic medicine used to dissolve blood clots that have formed in certain blood vessels and to restore the blood flow in these blocked vessels (=thrombolysis).</p><p>Rapilysin is used after an acute myocardial infarction (heart attack) in order to dissolve the blood clot causing the heart attack. It is given within 12 hours after the onset of symptoms.</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take rapilysin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take rapilysin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The doctor will ask you questions before giving you Rapilysin, to find out if you have an increased risk of bleeding.</p><p>Do not use Rapilysin</p><ul><li>if you are allergic to reteplase or any of the other ingredients of this medicine (listed in section 6).</li><li>if you have a bleeding disorder.</li><li>if you are taking medicine to thin your blood (oral anticoagulants, e.g. warfarin).</li><li>if you have a brain tumour or a malformed blood vessel or a vessel wall dilatation (aneurysm) in the brain.</li><li>if you have other tumours associated with an increased risk of bleeding.</li><li>if you have had a stroke.</li><li>if you have had external heart massage within the past 10 days.</li><li>if you have severe uncontrolled high blood pressure (hypertension).</li><li>if you have an ulcer in the stomach or small intestine.</li><li>if you have enlarged blood vessels in the gullet (oesophagus) (frequently caused by liver disease).</li><li>if you have severe liver or kidney disease.</li><li>if you have acute inflammation of the pancreas or pericardium (the sac surrounding the heart), or an infection of the heart muscle (bacterial endocarditis).</li><li>if you have in the past 3 months had severe bleeding, a major injury or major surgery (e.g. coronary artery bypass graft, or surgery or injury to the head or spine), given birth, or had an organ biopsy or other medical / surgical procedure. Warnings and precautions</li></ul><p>Bleeding The most common side effect of Rapilysin is bleeding. Therefore Rapilysin must be given only in the presence and under the instructions of an emergency doctor.</p><p>Pay careful attention to all possible bleeding sites (e.g. injection sites). Heparin, which is given together with Rapilysin, may also increase bleeding.</p><p>The risks of Rapilysin treatment may be increased if you have any of the following conditions:</p><ul><li>diseases of the blood vessels in the brain</li><li>systolic blood pressure higher than 160 mmHg</li><li>bleeding in the gastrointestinal, urinary or genital tract within the past 10 days</li><li>high likelihood of a blood clot in the heart (e.g. as a result of narrowing of a heart valve or atrial fibrillation)</li><li>septic inflammation of a vein with blood clotting (septic thrombophlebitis) or blocked blood vessels at an infected site</li><li>age over 75 years</li><li>any other condition in which bleeding might be especially dangerous or might occur at a site where it would be difficult to control At present, little data are available on the use of Rapilysin in patients with diastolic blood pressure higher than 100 mmHg.</li></ul><p>Abnormal heart beats (arrhythmias) Thrombolytic treatment may cause the heart to beat irregularly. Therefore tell the medical staff immediately if you</p><ul><li>feel palpitations or an irregular heart beat</li></ul><p>Repeated use At present there is no experience with repeated use of Rapilysin. Therefore, repeated use is not recommended. Antibody formation to the reteplase molecule has not been seen.</p><p>Children Safety and effectiveness of Rapilysin in children have not been established. Treatment of children with Rapilysin is not recommended.</p><p>Other medicines and Rapilysin: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Heparin and other medicines that thin the blood (anticoagulants) and acetylsalicylic acid (a substance used in many medicines used to relieve pain and lower fever) may increase the risk of bleeding.</p><p>For information on medicines that should not be physically mixed with Rapilysin solution for injection, see section 3. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Pregnancy There is no experience with Rapilysin in pregnant women. Therefore it should not be used except in life-threatening situations. You must tell your doctor if you are pregnant or think you are pregnant. Your doctor can tell you the risks and benefits of using Rapilysin during pregnancy.</p><p>Breast-feeding You should not breast-feed your baby during treatment with Rapilysin as it is not known whether Rapilysin is excreted into mother s milk. Mother s milk should be thrown away during the first hours after thrombolytic treatment. Discuss with your doctor when you can take up breast-feeding again.</p></div>
</text>
</section>
<section>
<title value="3. How to take rapilysin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take rapilysin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Rapilysin is usually given in a hospital. The medicine is supplied in vials as a powder for injection. Before use, the powder for injection must be dissolved in the water for injection supplied in the prefilled syringe that is in the package. Do not add any other medicines. The resulting solution must be used immediately. The solution must be examined to ensure that only clear, colourless solution is injected. If the solution is not clear and colourless it should be thrown away.</p><p>Treatment with Rapilysin 10 U should be started as soon as possible after the symptoms of heart attack begin.</p><p>Heparin and Rapilysin cannot be mixed in the same solution. Other medicines may also not mix well with Rapilysin. No other medicines should be added to the injection solution (see below). Rapilysin should be injected preferably through an intravenous line that is used only for the injection of Rapilysin. No other medicines should be injected through the line reserved for Rapilysin, either at the same time, or before or after Rapilysin injection. This applies to all medicines including heparin and acetylsalicylic acid, which are given before and after Rapilysin to reduce the risk of new blood clots forming. If the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % glucose solution before and after the Rapilysin injection.</p><p>Dosage of Rapilysin Rapilysin is given as a 10 U injection followed by a second 10 U injection 30 minutes later (double bolus).</p><p>Each injection should be given slowly within 2 minutes. The injection must not be given mistakenly outside the vein. Therefore, be sure to tell the medical staff if you experience pain during the injection.</p><p>Heparin and acetylsalicylic acid are given before and after Rapilysin to reduce the risk of new blood clots forming.</p><p>Dosage of Heparin The recommended dose of heparin is 5000 I.U. given as a single injection before Rapilysin, followed by an infusion of 1000 I.U. per hour starting after the second Rapilysin injection. Heparin should be given for at least 24 hours, preferably for 48-72 hours, in order to keep aPTT values 1.5 to 2 times normal.</p><p>Dosage of Acetylsalicylic Acid<br/>The dose of acetylsalicylic acid given before Rapilysin should be at least 250 mg-350 mg and should be followed by 75-150 mg/day, at least until discharge from hospital.</p><p>If more Rapilysin is used than recommended In the event of overdosage there may be an increased risk of bleeding.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Very common side effects (may affect more than 1 in 10 people)</p><ul><li>Bleeding at the injection site, e.g. blood blister (haematoma)</li><li>Chest Pain / angina, low blood pressure and heart failure /shortness of breath may reappear</li><li>Burning sensation when Rapilysin is injected</li></ul><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li>Bleeding in the digestive tract (e.g. bloody or black vomit, or stools) in the gums or in the urinary or genital tract</li><li>Abnormal heart beats (arrhythmias), cardiac arrest, circulatory collapse or another heart attack may occur</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>Bleeding around the heart, in the abdomen, the brain or the eyes, under the skin, from the nose or as coughed up blood</li><li>Damage to the heart or heart valves, or a blood clot in the lung, brain or other part of body mayoccur</li><li>hypersensitivity (e.g. allergic reactions)</li></ul><p>Very rare side effects (may affect up to 1 in 10,000 people)</p><ul><li>Events related to the nervous system (e.g. epileptic seizure, convulsion, speech disorder, delirium, agitation, confusion, depression, psychosis)</li><li>severe allergic reaction, causing shock or collapse</li></ul><p>Side effects of frequency not known (cannot be estimated from the available data)</p><ul><li>Blockage of blood vessels due to cholesterol (fat)</li></ul><p>Cardiovascular events can be life-threatening or cause death.</p><p>Patients with systolic blood pressure over 160 mmHg have a greater risk of bleeding in the brain. The risk of intracranial bleeding and fatal intracranial bleeding increases with increasing age. Blood transfusions were rarely required. Death or permanent disability are not uncommon in patients who have a stroke (including bleeding in the brain) or other serious bleeding problem.</p><p>Be sure to tell hospital staff immediately if any of these symptoms appear.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store rapilysin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store rapilysin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the label of the vial after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 25 C.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>After reconstitution ( when dissolved ), the solution must be used immediately.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Rapilysin contains</p><ul><li>The active substance is reteplase 10U/10 ml after reconstitution.</li><li>The other ingredients are:</li></ul><p>Powder: Tranexamic acid di-potassium-hydrogen phosphate phosphoric acid sucrose polysorbate Solvent: 10 ml Water for injection (prefilled syringe)</p><p>What Rapilysin looks like and contents of the pack Rapilysin is presented as a powder and a solvent for injection (0.56 g powder in a vial and 10 ml solvent in a pre-filled syringe with a reconstitution spike and a needle-pack of 2)</p><p>Marketing Authorisation Holder and Manufacturer</p><p>Marketing Authorisation Holder Actavis Group PTC ehf. Dalshraun 1 220 Hafnarfj r ur Iceland</p><p>Manufacturer Actavis Italy S.p.A.<br/>Nerviano Plant Via Pasteur 20014 Nerviano (Milan) Italy</p><p>Cenexi 52, Rue Marcel et Jacques Gaucher 94120 Fontenay-Sous-Bois France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG T l/Tel: +32 38207Lietuva UAB Teva Baltics Tel: +370 52660</p><p>Te : +359 24899Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien T l/Tel: +32 38207 esk republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007Magyarorsz g Teva Gy gyszergy r Zrt Tel: +36 12886Danmark Teva Denmark A/S Tlf: +45 44985Malta Teva Pharmaceuticals Ireland L-Irlanda Tel: +44 2075407Deutschland ratiopharm GmbH Tel: +49 73140Nederland Teva Nederland B.V. Tel: +31 8000228Eesti UAB Teva Baltics Eesti filiaal Tel: +372 6610Norge Teva Norway AS Tlf: +47 66775<br/>Specifar A.B.E.E. : +30 2118805 sterreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970Espa a Teva Pharma, S.L.U. Tel: +34 913873Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459France Teva Sant<br/>T l: +33 155917Portugal Teva Pharma - Produtos Farmac uticos, Lda. Tel: +351 214767Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720Rom nia Teva Pharmaceuticals S.R.L. Tel: +40 212306Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890 sland Teva Pharma Iceland ehf. S mi: +354 5503Slovensk republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267Italia Teva Italia S.r.l. Tel: +39 028917Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805K<br/>Specifar A.B.E.E.</p><p>: +30 2118805Sverige Teva Sweden AB Tel: +46 42121Latvija UAB Teva Baltics fili le Latvij<br/>Tel: +371 67323United Kingdom (Northern Ireland) Accord Healthcare Ireland Ltd. Ireland Tel: +353 214619This leaflet was last revised in <{MM/YYYY}></p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp4ddd1ab0c737d818a0282b987d49df2b"/>
<resource>
<MedicinalProductDefinition>
<id value="mp4ddd1ab0c737d818a0282b987d49df2b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp4ddd1ab0c737d818a0282b987d49df2b"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp4ddd1ab0c737d818a0282b987d49df2b</b></p><a name="mp4ddd1ab0c737d818a0282b987d49df2b"> </a><a name="hcmp4ddd1ab0c737d818a0282b987d49df2b"> </a><a name="mp4ddd1ab0c737d818a0282b987d49df2b-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/96/018/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Rapilysin 10 U powder and solvent for solution for injection.</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/96/018/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Rapilysin 10 U powder and solvent for solution for injection."/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
